- Home
- CRVO vs PMVP Comparison
CRVO vs PMVP Comparison
Compare CRVO & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVO
- PMVP
- Stock Information
- Founded
- CRVO 2001
- PMVP 2013
- Country
- CRVO United States
- PMVP United States
- Employees
- CRVO N/A
- PMVP N/A
- Industry
- CRVO Biotechnology: Pharmaceutical Preparations
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- CRVO Health Care
- PMVP Health Care
- Exchange
- CRVO Nasdaq
- PMVP Nasdaq
- Market Cap
- CRVO 67.4M
- PMVP 76.8M
- IPO Year
- CRVO N/A
- PMVP 2020
- Fundamental
- Price
- CRVO $7.45
- PMVP $1.47
- Analyst Decision
- CRVO Strong Buy
- PMVP Strong Buy
- Analyst Count
- CRVO 6
- PMVP 1
- Target Price
- CRVO $19.17
- PMVP $5.00
- AVG Volume (30 Days)
- CRVO 109.4K
- PMVP 597.2K
- Earning Date
- CRVO 11-11-2025
- PMVP 11-06-2025
- Dividend Yield
- CRVO N/A
- PMVP N/A
- EPS Growth
- CRVO N/A
- PMVP N/A
- EPS
- CRVO N/A
- PMVP N/A
- Revenue
- CRVO $7,776,968.00
- PMVP N/A
- Revenue This Year
- CRVO N/A
- PMVP N/A
- Revenue Next Year
- CRVO N/A
- PMVP N/A
- P/E Ratio
- CRVO N/A
- PMVP N/A
- Revenue Growth
- CRVO N/A
- PMVP N/A
- 52 Week Low
- CRVO $1.80
- PMVP $0.81
- 52 Week High
- CRVO $16.94
- PMVP $1.84
- Technical
- Relative Strength Index (RSI)
- CRVO 38.31
- PMVP 55.04
- Support Level
- CRVO $7.03
- PMVP $1.38
- Resistance Level
- CRVO $8.38
- PMVP $1.50
- Average True Range (ATR)
- CRVO 0.54
- PMVP 0.10
- MACD
- CRVO -0.10
- PMVP 0.01
- Stochastic Oscillator
- CRVO 11.00
- PMVP 82.50
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.